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microRNAs (miRNAs) bind to Argonaute (Ago)
proteins and inhibit translation or promote deg-
radation of mRNA targets. Human let-7 miRNA
inhibits translation initiation of mRNA targets
in an m7G cap-dependent manner and also ap-
pears to block protein production, but the mo-
lecular mechanism(s) involved is unknown and
the role of Ago proteins in translational regula-
tion remains elusive. Here we identify a motif
(MC) within the Mid domain of Ago proteins,
which bears significant similarity to the m7G
cap-binding domain of eIF4E, an essential
translation initiation factor. We identify con-
served aromatic residues within the MC motif
of human Ago2 that are required for binding to
them7G cap and for translational repression but
do not affect the assembly of Ago2 with miRNA
or its catalytic activity. We propose that Ago2
represses the initiation of mRNA translation by
binding to the m7G cap of mRNA targets, thus
likely precluding the recruitment of eIF4E.
INTRODUCTION
microRNAs (miRNAs) and short interfering RNAs (siRNAs)
are 22 nucleotide (nt) noncoding RNAs that regulate
gene expression by binding to recognition elements (such
as miRNA recognition elements—MREs) in their RNA tar-
gets (reviewed in Ambros [2004], Bartel [2004], and Mello
and Conte [2004]). miRNAs and siRNAs assemble with
Argonaute proteins in effector complexes known as RNA-
induced silencing complexes (RISCs) or miRNPs (Ham-
mond et al., 2001; Mourelatos et al., 2002; Martinez et al.,
2002; Hutvagner and Zamore, 2002; Tomari and Zamore,
2005). Argonaute proteins are a large family of 95 Kda p-
roteins that contain two signature motifs known as PAZ
and PIWI and are found in most organisms (Carmell
et al., 2002). Further division of Argonaute proteins intwo subfamilies termed Ago and PIWI families is based
on sequence similarities between the founding members
of each subclass, the AGO1 protein from Arabidopsis
and the PIWI protein from Drosophila melanogaster, re-
spectively (Carmell et al., 2002). Ago proteins bind directly
to miRNAs and to siRNAs and are the core protein compo-
nents of RISCs/miRNPs (Hammond et al., 2001; Mourela-
tos et al., 2002; Martinez et al., 2002; Hutvagner and
Zamore, 2002; Tomari and Zamore, 2005; Murchison and
Hannon, 2004; Meister and Tuschl, 2004).
The molecular function of miRNAs and siRNAs depends
on which Ago protein they bind to and on the degree of
complementarity with their cognate MREs. If the comple-
mentarity of a miRNA or siRNA with its target mRNA is ex-
tensive and the miRNA assembles with catalytically active
Ago proteins, the target mRNA is cleaved at a position
across from the middle of the guide miRNA or siRNA
(Elbashir et al., 2001; Hutvagner and Zamore, 2002; Liu
et al., 2004; Meister et al., 2004). Biochemical, genetic,
and crystallographic studies of Ago proteins have shown
that the PIWI domain of Ago proteins adopts an RNase
H fold (Song et al., 2004; Parker et al., 2004; Yuan et al.,
2005) and in certain Ago proteins such as mammalian
Ago2 provides the endonuclease activity that catalyzes
miRNA- and siRNA-directed mRNA cleavage (Liu et al.,
2004; Meister et al., 2004).
Partial complementarity between miRNA and MREs
leads to translational repression and/or accelerated deg-
radation of the targeted mRNA, but the mechanism of this
regulation is not well understood. In human HeLa cells, the
let-7 miRNA inhibits the initiation of translation of a reporter
construct bearing MREs for let-7 in its 30-UTR and leads to
sequestration of the repressed mRNA in processing bod-
ies (PBs) in a cap-dependent manner (Pillai et al., 2005).
PBs are cytoplasmic bodies enriched in mRNA decay
enzymes, where translationally repressed mRNAs are
localized (Sheth and Parker, 2003). In PBs mRNAs can
undergo decapping and degradation (Sheth and Parker,
2003). There is evidence that some miRNA or siRNA-tar-
geted mRNAs can also be sequestered in PBs (Liu et al.,
2005b; Sen and Blau, 2005; Pillai et al., 2005). Under cer-
tain conditions, this sequestration can be reversible, as inCell 129, 1141–1151, June 15, 2007 ª2007 Elsevier Inc. 1141
the case of human hepatoma Huh7 cells, where miR-122
inhibits translation initiation of its endogenous CAT-1
mRNA target and sequesters it to PBs (Bhattacharyya
et al., 2006). Interestingly, this inhibition is reversed by
stress, which leads to release of the CAT-1 mRNA from
PBs and its recruitment to polysomes (Bhattacharyya
et al., 2006). In these instances, the targeted mRNA is
not destabilized or undergoes a secondary, usually limited
degradation (Bhattacharyya et al., 2006; Pillai et al., 2005).
Human let-7 miRNA also appears to block production of
a reporter protein that is expressed from a construct con-
taining the 30-UTR of lin-41 (which contains two MREs for
let-7), on actively translating ribosomes (Nottrott et al.,
2006). Interestingly, the stability of the targeted mRNA
may be influenced by the structure of the miRNA:MRE
heteroduplex. In HeLa cells, MREs for let-7 in the 30-UTR
of reporter constructs that contain a single bulge when
base-paired with let-7, are potent translational repressors
but do not destabilize the targeted mRNA (Kiriakidou et al.,
2004; Schmitter et al., 2006). In contrast, MREs that con-
tain two opposing loops when base-paired with let-7, in
addition to translational repression, lead to degradation
of the targeted mRNA. This is proposed to be a secondary
consequence of translational repression (Schmitter et al.,
2006).
In C. elegans, the lin-4 miRNA cosediments with its
mRNA target lin-14 in polysomes during repression, sug-
gesting that inhibition of translation may occur at a step
after initiation (Olsen and Ambros, 1999), although more
recent reports showed significant degradation of lin-14
mRNA during lin-4-mediated repression (Bagga et al.,
2005). Inhibition of translation after initiation by trans-
fected siRNAs has also been demonstrated in human cells
(Petersen et al., 2006). However, another group using the
same siRNAs and reporter constructs found that the inhi-
bition was at the level of translation initiation (Humphreys
et al., 2005). Finally, independently of translational repres-
sion, destabilization of mRNAs targeted by miRNAs may
also occur (Rehwinkel et al., 2005; Wu et al., 2006; Giral-
dez et al., 2006).
The protein complexes mediating miRNA-dependent
translational repression are not well defined. Ago proteins
are the leading protein candidates due to their engage-
ment with miRNAs. Artificial tethering of human Ago pro-
teins to the 30-UTR of reporter constructs leads to inhibition
of translation initiation without affecting the mRNA levels of
the reporters (Pillai et al., 2004; Pillai et al., 2005). Other
proteins, such as GW182, the decapping enzyme complex
Dcp1 and Dcp2, and RCK/p54, a general translation inhib-
itor, can also participate in miRNA-dependent translational
repression and mRNA degradation. (Liu et al., 2005a,
2005b ; Rehwinkel et al., 2005 ; Chu and Rana, 2006).
The 50 end of eukaryotic mRNAs is modified by the ad-
dition of a 7-methyl guanosine cap (m7GpppN; m7G cap;
where N is any nucleotide) in a 50-50 triphosphate linkage.
Eukaryotic initiation factor 4E (eIF4E) binds the m7G cap
directly, and this interaction is essential for the initiation
of translation of most eukaryotic mRNAs (reviewed in1142 Cell 129, 1141–1151, June 15, 2007 ª2007 Elsevier Inc.Merrick [2004], Gebauer and Hentze [2004], and Richter
and Sonenberg [2005]). Regulation of translation initiation
is the most common target of translational control, and
preventing binding of eIF4E to the m7G cap is a commonly
employed cellular strategy to inhibit translation (Richter
and Sonenberg, 2005; Gebauer and Hentze, 2004).
In this study we present evidence that a subdomain
within the middle domain of Ago2 demonstrates m7G
cap binding activity and is required for translational re-
pression but not for assembly with miRNA or endonucleo-
lytic activity. We propose that Ago2 represses the initia-
tion of mRNA translation by binding to the m7G cap of
mRNA targets, thus likely precluding the recruitment of
eIF4E.
RESULTS
A Cap-Binding-like Domain (MC) within Ago2
We undertook a bioinformatics approach to study the pri-
mary structure of Argonaute proteins. BLAST searches of
the Swiss-Prot database showed that there was significant
similarity between a portion of the middle (Mid) domain of
human Argonaute 2 (hAGO2) encompassing amino acids
468–520, which we term the MC domain, with the human
eIF4E. The MC domain is present in all four human and
mammalian Agos, in Agos from chordates (such as zebra-
fish), in Drosophila AGO1, and in C. elegans ALG-1 and
ALG-2. This domain is not found in Ago proteins of plants,
archaea, or fission yeast, in Drosophila AGO2 and in most
members of theC. elegans Ago protein family, with the ex-
ception of ALG-1 and ALG-2. In addition, the MC domain is
absent from proteins of the PIWI family (Figure 1 and our
unpublished data).
Biochemical and crystallographic analyses of m7G cap-
binding proteins show that the most important determi-
nants of cap recognition are p-p stacking interactions be-
tween the methylated base of the cap (m7G) and the side
chains of two protein aromatic residues. In the case of
eIF4E the m7G is sandwiched between the side chains
of two tryptophan residues, W56 and W102 (numbering
refers to the murine and human eIF4E) (Marcotrigiano
et al., 1997). Substitution of these tryptophan residues
with phenylalanines still supports cap binding but with re-
duced affinity (Altmann et al., 1988). In human 4EHP, an
eIF4E homologous protein with orthologs in nematodes
(IFE-4) and plants (nCBP), the m7G is sandwiched be-
tween the side chains of a tyrosine (Y78) and a tryptophan
residue (W124) (Rom et al., 1998). In cap-binding protein
20 (CBP20), the m7G is sandwiched between the side
chains of two tyrosine residues (Y20 and Y43 of human
CBP20) (Calero et al., 2002). In VP39, a vaccinia virus pro-
tein, the m7G is sandwiched between the side chains of
a tyrosine (Y22) and phenylalanine (F180) residues (Hodel
et al., 1997; Hu et al., 1999). It is interesting to note that
although CBP20 and VP39 do not show any homology
with eIF4E, they bind the cap by using the same strategy:
stacking interactions between aromatic residues and
the m7G.
Figure 1. Similarity between the MC
Domain of Ago Proteins and the m7G
Cap-Binding Domain of eIF4E
(A) Indicated sequences were aligned using
CLUSTALW. Arrows indicate the two trypro-
phan residues (W56 and W102) of eIF4E that
bind to the m7G cap and the conserved phenyl-
alanines (F) of Ago proteins. The two phenylal-
anines of hAgo2 (F470 and F505) that were mu-
tated to valines or tryptophans are underlined.
Accession numbers are listed in parentheses;
(*) indicates identical and (#) indicates similar.
(B) Alignments of cap-binding domains of
eIF4E homologs.The similarity between the MC domain of Ago proteins
and eIF4E encompasses the m7G cap-binding domain
of eIF4E and is centered around W56 and W102, the two
tryptophan residues of eIF4E that are crucial for m7G bind-
ing. In Ago proteins these tryptophans are replaced by two
phenylalanines (F470 and F505), conserved aromatic res-
idues (Figure 1). This similarity between the cap-binding
domain of eIF4E and Agos prompted us to ask whether
Ago proteins might bind to the m7G cap.
Specific Interactions between Ago2
and a Cap-Analog Resin
To test whether human Ago2 associates with the m7G cap,
we transfected human 293T cells with vectors expressing
HA-tagged, wild-type Ago2 or mutant Ago2F470V;F505V
(Ago2-F2V2) where the two phenylalanines (F470 and
F505) of the Ago2 MC domain were substituted with va-
lines. The overexpressed, wild-type, and mutant Ago2 pro-
teins were purified with immunoaffinity chromatographyusing agarose beads with covalently bound anti-HA anti-
body, followed by acidic elution of the HA-tagged proteins,
neutralization, and dialysis (Figure 2A). The eluted proteins
were then tested for binding to m7GTP sepharose or GTP-
sepharose. The binding buffer included heparin to elimi-
nate nonspecific interactions between the basic Ago2
protein and the negatively charged m7GTP or GTP. After
extensive washes, retained proteins were analyzed by
NuPAGE electrophoresis and western blotting. As shown
in Figure 2B, Ago2 (lane 2), but not Ago2-F2V2 (lane 7),
bound to the m7GTP sepharose. To further characterize
the specificity of this interaction, we carried out m7GTP
sepharose-binding reactions including m7GpppG cap an-
alog as a competitive inhibitor or nonmethylated GpppG.
As shown in Figure 2B, the presence of the methylated
cap analog competed with binding of Ago2 to the m7GTP
sepharose (lane 3), whereas the presence of nonmethy-
lated GpppG did not affect retention of the Ago2 to the
m7GTP sepharose (lane 4); wild-type Ago2 protein did notFigure 2. Human Ago2 Binds to m7GTP
Sepharose, and This Interaction Is Abol-
ished byMutations of the TwoConserved
Phenylalanines of the MC Domain in
Ago2-F2V2 Mutant
(A) Wild-type human lN-HA-Ago2 or point
mutant lN-HA-Ago2F470V;F505V (lN-HA-Ago2-
F2V2) was immunoaffinity purified and eluted.
(B) Purified proteins were incubated with
m7GTP sepharose, a cap analog resin, in the
presence or absence of m7GpppG competi-
tive inhibitor, or nonmethylated cap analog
(GpppG), or they were incubated with GTP se-
pharose. Lanes 1 and 6 show 5% of input frac-
tion used for binding. Bound proteins were
analyzed by Western blot with 16B12 anti-HA
monoclonal antibody.Cell 129, 1141–1151, June 15, 2007 ª2007 Elsevier Inc. 1143
bind to nonmethylated GTP sepharose (lane 5). Ago2-
F2V2 mutant did not bind to m7GTP sepharose or GTP
sepharose under any conditions (Figure 1B, lanes 7–10).
Taken together these results demonstrate that Ago2
associates specifically with m7G and that the two con-
served phenylalanines of the MC domain are required for
binding.
TheMCDomain of Ago2 Is Required for Translational
Repression but Not for Endonucleolytic Activity
The Filipowicz lab has previously shown that tethering of
all human Ago proteins (Ago1–4) to the 30-UTR of a Renilla
Luciferase reporter represses translation without affecting
the mRNA levels of the reporter, and this is similar to the
inhibition of translation initiation by let-7 miRNA (Pillai
et al., 2004, 2005). We employed the same strategy (shown
in Figure 4A) to test whether mutations of the two phenyl-
alanines (F470 and F505) of the MC domain of human
Ago2 also abolish the inhibitory effect of Ago2 in transla-
tion. Briefly, the tethering assay involves the creation of
a fusion protein between Ago2 or Ago2-F2V2 and the lN
peptide, a 22 amino acid peptide derived from the l
phage, which binds with high affinity to its cognate RNA-
binding site, known as BoxB (Legault et al., 1998). Five
BoxB sites are placed in the 30-UTR of an RL reporter con-
struct (RL-5BoxB), and the effect of the fusion proteins to
the reporter is assessed in cotransfection experiments (De
Gregorio et al., 1999; Pillai et al., 2004, 2005). An Ago2
construct that does not contain the lN peptide serves as
negative control, and an HA epitope placed at the amino
terminus of Ago2 or Ago-F2V2 serves as a tag to detect
the proteins by western blot and for immunoprecipitation
experiments.
First, we wanted to test whether the lN and HA tags
and more importantly the mutations of the two phenylala-
nine residues in Ago-F2V2 affected the activity of the
fusion proteins. Pillai et al. have previously shown that
lN-HA-Ago2 was catalytically active (Pillai et al., 2004).
We transfected HeLa cells with HA-Ago2, lN-HA-Ago2,
and lN-HA-Ago2-F2V2 constructs and performed immu-
noprecipitations with anti-HA antibody beads. We then
tested whether the immunoprecipitated proteins were
able to cleave a radiolabeled RNA target complementary
to the endogenous let-7 miRNA (let7-TP target, shown in
Figure 3A). As positive control, we used beads containing
endogenous human Ago2 protein obtained after immuno-
precipitation with the 2A8 anti-Ago monoclonal antibody.
We used anti-HA immunoprecipitates from mock-trans-
fected HeLa cells as negative control. As shown in Fig-
ure 3B, HA-Ago2, lN-HA-Ago2, and lN-HA-Ago2-F2V2
were able to cleave the let7-TP RNA target. These findings
indicate that the transfected proteins, including the Ago2-
F2V2 mutant, are able to assemble with endogenous let-7
in HeLa cells into catalytically active Ago2/miRNA ribonu-
cleoprotein complexes. Thus, the two point mutations in
Ago2-F2V2 did not perturb the folding or structural prop-
erties of Ago2.1144 Cell 129, 1141–1151, June 15, 2007 ª2007 Elsevier Inc.Next, we transfected HeLa cells with HA-Ago2, lN-HA-
Ago2, and lN-HA-Ago2-F2V2 along with RL-5BoxB and
firefly luciferase (FL; as normalization control) and quanti-
tated the levels of normalized RL/FL using standard lumi-
nometric assays. As shown in Figure 4B, lN-HA-Ago2
led to a 4-fold repression of RL-5BoxB, as previously re-
ported (Pillai et al., 2004, 2005). In contrast, lN-HA-Ago2-
F2V2 was unable to repress the expression of RL-5BoxB.
We next tested the protein levels of the transfected Ago2
constructs by probing HeLa cell lysates with anti-HA anti-
body and also with anti-b-tubulin antibody, as loading
control. As shown in Figure 4C, all transfected Ago2 pro-
teins were expressed in similar levels. Finally, we assayed
the mRNA levels of RL-5BoxB by Northern blotting using
radiolabeled riboprobes against RL and against FL (as
normalization control). As shown in Figure 4D, the mRNA
levels of RL-5BoxB were similar between the samples
that were transfected with HA-Ago2, lN-HA-Ago2, or
lN-HA-Ago2-F2V2. We also tested whether translation
initiated at an internal ribosome entry site (IRES), and
thus bypassing the cap, was subjected to repression by
Figure 3. lN-HA-Ago2-F2V2 Assembles with Endogenous
let-7 miRNA and Contains an Active Endonuclease Domain
(A) Schematic of the RNA target (let7-TP) and the base-pairing with let-
7a (blue); the [50-32P] of pCp is shown in red. Cleavage site is indicated
with red lightning bolt.
(B) The 30-end radiolabeled let7-TP RNA target was incubated with
beads containing indicated immunoprecipitated proteins; mock refers
to mock-transfected cells (negative control); 2A8 is an anti-Ago mono-
clonal antibody and served as positive control. The products of the
reactions were analyzed on 20% denaturing polyacrylamide gel.
Nucleotide sizes of the radiolabeled marker (M) are shown on the left.
Figure 4. lN-HA-Ago2 Represses Trans-
lation in anm7G Cap-Dependent Manner,
but lN-HA-Ago2 F2V2 Is Unable to
Repress Translation
(A) Schematic of the lN-tethering assay, the
capped RL-5BoxB reporter, and the Ago2
constructs used.
(B) HeLa human cells were cotransfected with
Renilla Luciferase RL-5BoxB bearing 5BoxB-
binding sites for lN in the 30-UTR, along with
firefly luciferase (FL; as a normalization control)
and the indicated Ago constructs. Results
shown are average values (with standard devi-
ations) of normalized RL/FL activities obtained
from six separate experiments.
(C) Protein levels of indicated HA-tagged Ago
proteins were analyzed by western blots (WB)
of lysates from transfected cells; b-tubulin
served as normalization control.
(D) mRNA levels of RL-5BoxB and FL (as a nor-
malization control) were analyzed by Northern
blot (NB) of lysates from transfected cells using
radiolabeled riboprobes and quantitated with
storage phosphor autoradiography. The ratio
of RL-5BoxB mRNA to FL mRNA is shown
under each lane.
(E) Schematic of the uncapped, IRES-driven,
reporter mRNA (EMCV-RL-5BoxB), and the
Ago2 constructs used.
(F) 293 human cells were first transfected with
the indicated Ago constructs and then trans-
fected with uncapped EMCV-RL-5BoxB mRNA
and FL mRNA (as a normalization control). Re-
sults shown are average values (with standard
deviations) of normalized RL/FL activities ob-
tained from four separate experiments.tethered Ago2. As shown in Figures 4E and 4F, the trans-
lation of transfected reporter RNA containing the IRES of
the encephalomyocarditis virus (EMCV RL-5BoxB) was
not repressed by tethered Ago2.
These results demonstrate that translational repression
by Ago2 requires an m7G cap and cancellation of the cap
binding activity of Ago2 by mutations of the two conserved
phenylalanines (F470 and F505) of the MC domain abol-
ishes the effect of Ago2 on translation. The mRNA levels
of the reporter are not affected. Furthermore, these muta-
tions do not affect the ability of Ago2-F2V2 to assemble
with miRNAs or its catalytic activity. Thus, we have effec-
tively dissected the inhibitory activity of Ago2 in translation
from its endonucleolytic activity.
The MC Domain of Ago2 Mediates Inhibition
of Translation Initiation
We next analyzed the polysome profiles of RL-5BoxB
mRNA in HeLa cells transfected with HA-Ago2, lN-HA-
Ago2, or lN-HA-Ago2-F2V2. Cytoplasmic lysates from
transfected HeLa cells were subjected to sedimentation
on 10%–50% sucrose gradients in the presence of cyclo-
heximide (to preserve the association of translating ribo-
somes with mRNAs). The gradients were divided in 12
equal-volume fractions, and the position of soluble, light
particles, 40S subunits, monoribosomes, and heavierCsedimenting polyribosomes was monitored with continu-
ous A254 measurements during fractionation. Total RNA
was isolated and equal-volume aliquots were fractionated
by electrophoresis (Figure S1 shows the ethidium bro-
mide-stained gels) and analyzed by Northern blots using
radiolabeled riboprobes against RL-5BoxB mRNA or
DNA probes against endogenous b-actin mRNA. The sed-
imentation of b-actin mRNA is an accurate indicator for the
position and integrity of polysomes, since almost all b-
actin mRNA is actively translated. As shown in Figure 5A,
a significant fraction of RL-5BoxB mRNA was shifted to
the light fractions in the presence of lN-HA-Ago2, as pre-
viously reported Pillai et al. (2005), indicating a translation
initiation block. In contrast, in the presence of HA-Ago2 or
lN-HA-Ago2-F2V2, most of RL-5BoxB mRNA is found
toward the bottom of the gradient, cosedimenting with ac-
tively translating polysomes (Figures 5B and 5C). These
results (quantitation shown in Figure 5D) indicate that
mutations abolishing the cap-binding activity of Ago2
are also unable to negatively regulate translation of its
mRNA target.
Specific Aromatic Amino Acids in the MC Domain
of Ago2 Mediate Translational Repression
We next asked whether a single-valine mutation of the MC
domain of Ago2 (F470) would be sufficient to cancel theell 129, 1141–1151, June 15, 2007 ª2007 Elsevier Inc. 1145
Figure 5. lN-HA-Ago2-F2V2, Unlike
Wild-Type lN-HA-Ago2, Cannot Inhibit
Translation Initiation
(A)–(C) Polysomal profiles from HeLa cells that
had been cotransfected with Renilla Luciferase
RL-5BoxB (bearing 5BoxB-binding sites for
lN in the 30-UTR), along with lN-HA-Ago2 (A),
lN-HA-Ago2-F2V2 (B), or HA-Ago2 (C) were
analyzed by sucrose gradient sedimentation.
RNA was extracted from each fraction and
analyzed with probes for RL-5BoxB and en-
dogenous b-actin on Northern blots (NB).
(D) Quantitation of mRNA distribution plotted
as percent of total radioactivity present in
each lane.translational regulatory activity of Ago2 and whether the
translational repressive activity of Ago2 would be affected
by substitution of one or both phenylalanines of the MC
domain (F470 alone or F470 and F505) by tryptophans
(mimicking the cap-binding domain of eIF4E, which utilizes
tryptophans to engage the cap). Using the tethering assay
described above, we transfected HeLa cells with lN-HA-
Ago2, lN-HA-Ago2-F1V1(Ago2F470V), lN-HA-Ago2-F2V2
(Ago2F470V;F505V), lN-HA-Ago2-F1W1(Ago2F470W), or lN-
HA-Ago2-F2W2(Ago2F470W;F505W) along with RL-5BoxB
and FL plasmids. As shown in Figure 6A, both lN-HA-
Ago2-F1V1 and lN-HA-Ago2-F2V2 were unable to repress
the translation of RL-5BoxB, whereas lN-HA-Ago2-F1W1
and lN-HA-Ago2-F2W2 restored translational regulatory1146 Cell 129, 1141–1151, June 15, 2007 ª2007 Elsevier Inc.activity, as compared to the wild-type lN-HA-Ago2. The
lN-HA-Ago2-F2V2 and lN-HA-Ago2-F2W2 mutants
were also tested in human 293T cells with similar results
(Figure 6B). These findings highlight the importance of
the two aromatic residues of the MC domain of Ago2 in
translational repression and support a model (Figure 7) in
which the MC domain of Ago2 protein exerts translational
repression via interaction with the m7G cap.
DISCUSSION
Our findings support a model where the MC domain of
Ago2 represses mRNA translation by binding to the m7G
cap of mRNA targets. We propose a model where bindingFigure 6. lN-HA-Ago2-F1V1 Single Mu-
tant Is Unable to Repress Translation
while Substitution of Phenylalanines
by Tryptophans Restores Translational
Repressing Activity of Ago2
(A and B) HeLa (A) or 293T (B) human cells were
cotransfected with Renilla Luciferase RL-
5BoxB bearing 5BoxB-binding sites for lN in
the 30-UTR, along with firefly luciferase (FL; as
a normalization control) and the indicated
Ago2 constructs. Results shown are average
values (with standard deviations) of normalized
RL/FL activities obtained from ten (A) or nine (B)
separate experiments. Protein levels of indi-
cated HA-tagged Ago proteins were analyzed
by western blots (WB) of lysates from trans-
fected cells; hnRNP-A1 served as normaliza-
tion control.
of the m7G cap by Ago2 precludes the recruitment of eIF4E
(Figure 7). In this model, the miRNA acts as a specificity de-
terminant to deposit the Ago2 protein onto mRNA targets
and provides a simple and direct way to explain inhibition
of translation initiation as seen by mammalian miRNAs
and first proposed by the Filipowicz lab (Pillai et al.,
2005). Additional mechanisms, such as inhibition of protein
production on actively translating ribosomes or ribosome
dropoff during elongation, and additional factors such as
GW182, Dcp1, Dcp2, and RCK/p54, may function with
Ago proteins and miRNAs for optimal repression in vivo.
An important feature of miRNA-directed translational
repression is its apparent cooperativity: increasing the
number of MREs in the 30-UTR of an mRNA target en-
hances translational repression (Doench et al., 2003; Bar-
tel, 2004; Pillai et al., 2005). Cooperativity is also seen when
multiple MREs for different miRNAs are found in the 30-UTR
of the same mRNA target, arguing that common factors,
notably Ago proteins, bound to all miRNAs are responsible
for the enhanced translational repression (Krek et al.,
2005). Indeed, this cooperativity is accurately recapitu-
lated in experiments with tethered Ago2; increasing the
number of BoxB sites in the 30-UTR of the reporter leads
to enhancement of the translational repression by lN-
HA-Ago2 (Pillai et al., 2004). We propose that multiple
MREs, within the same mRNA target, increase the number
of Ago2 molecules bound to the mRNA, thus increasing the
probability that they will interact with the m7G cap and aug-
ment translational repression by limiting availability of the
m7G cap to eIF4E. In this model, Ago2 binds to m7G cap
less efficiently than eIF4E. Therefore, optimal repression
Figure 7. Proposed Mechanism of Translational Repression
by Ago2
miRNA-guided deposition of Ago2 to an mRNA target leads to binding
of the MC domain of Ago2 to the mRNA cap (m7G) and thus exclusion
of eIF4E and inhibition of translation initiation.Cby Ago2 and thus optimal eIF4E competition would require
multiple Ago2 molecules. Weak Ago2 binding to the m7G
cap also makes biological sense, since an Ago2 protein
with high affinity to the m7G cap would lead to generalized
and strong translational inhibition. Our model is also con-
sistent with weak translational repression of mRNA targets
that bear single MREs. Indeed, the vast majority of mRNA
targets contain a single MRE for any given miRNA and the
level of translational repression is typically modest (usually
1.5- to 2-fold repression) (Poy et al., 2004; Kiriakidou et al.,
2004; Stark et al., 2005; Farh et al., 2005). Such modest
and noncomplete repression may also explain why many
miRNAs cosediment with actively translating, endoge-
nous, mRNAs in polysomes (Nelson et al., 2004; Kim
et al., 2004; Maroney et al., 2006). Lastly, our findings do
not exclude additional mechanisms of miRNA and Ago
regulation, perhaps in the presence of additional factors
such as inhibition of protein production on actively trans-
lating ribosomes (Olsen and Ambros, 1999; Petersen et al.,
2006; Nottrott et al., 2006) or ribosome dropoff (Petersen
et al., 2006) during elongation or degradation of mRNAs
(Rehwinkel et al., 2005; Wu et al., 2006; Giraldez et al.,
2006).
An important observation is that the MC motif is not de-
tected in Ago proteins from organisms that do not contain
miRNAs, or do not use miRNAs for translational repres-
sion. Specifically, all mammalian Ago proteins and certain
Ago proteins from nematodes and flies, where transla-
tional repression by miRNAs has been demonstrated,
contain the MC domain, and thus these Ago proteins
may be capable of repressing translation. The MC domain
is present in Drosophila AGO1, which is required for
miRNA function, but not in Drosophila AGO2, which func-
tions predominantly in siRNA pathways (Kataoka et al.,
2001; Okamura et al., 2004), although more recent studies
show overlapping functions of Ago1 and Ago2 pathways
in flies (Meyer et al., 2006). The MC domain is present in
C.elegans ALG-1 and ALG-2 Ago proteins but absent
from the remaining 25 members of the C.elegans Argo-
naute protein family, consistent with the finding that there
are distinct RNAi-related pathways in nematodes, with
ALG-1 and ALG-2 proteins participating in the microRNA
pathway and all other nematode Argonaute proteins being
associated with exo- or endo-RNAi pathways (Yigit et al.,
2006). Finally, the MC domain is absent from Ago proteins
in organisms that do not have miRNAs such as fission
yeast and Archaea. Although the MC motif is not found
in Archaeal Agos, the structures of the P. furiosus and
A. aeolicus Ago proteins show that a major portion of the
Mid domain is accessible and thus may be capable of in-
teracting with other factors (Song et al., 2004; Yuan et al.,
2005). The MC domain is also not present in PIWI proteins,
which are almost exclusively expressed in the germline
(reviewed in Kim [2006]). Notably, tethering of HIWI, a hu-
man PIWI protein, in the 30-UTR of RL-5BoxB, is unable to
repress RL translation (Pillai et al., 2004). In contrast, teth-
ering of all human Ago proteins (Ago1–4) in the 30-UTR of
RL-5BoxB results in strong repression of RL translationell 129, 1141–1151, June 15, 2007 ª2007 Elsevier Inc. 1147
(Pillai et al., 2004). These studies along with the finding
that translational repression is unaffected in Ago2 null
mouse embryonic fibroblasts (Liu et al., 2004) also show
that the endonuclease activity of mammalian Ago proteins
is not required for translational repression. In flies, PIWI
proteins associate with repeat-associated siRNAs (Vagin
et al., 2006; Saito et al., 2006). Mammalian PIWI proteins
do not assemble with miRNAs or siRNAs but bind to
slightly larger RNAs termed piRNAs (Aravin et al., 2006;
Girard et al., 2006; Lau et al., 2006; Grivna et al., 2006a;
Watanabe et al., 2006). The mouse MIWI protein can asso-
ciate with m7GTP sepharose, suggesting that MIWI pro-
teins may also function in translation (Grivna et al., 2006b).
However, since the MC domain is absent from the MIWI
protein, it is possible that MIWI contains another cap-
binding motif or associates with the cap-analog resin indi-
rectly, via interactions with another cap-binding protein.
However, the biochemical function of MIWI proteins and
of piRNAs is unknown, and it is difficult to ascertain the
functional consequences of this interaction at this point.
Finally, the absence of the MC motif from plant Agos is in-
triguing and suggests that plant miRNAs may not be capa-
ble of repressing translation through interactions with the
cap (but other mechanisms cannot be excluded). So far
translational repression by miRNAs in plants has only
been implicated for the control of very few mRNA targets
(Aukerman and Sakai, 2003; Chen, 2004; Gandikota et al.,
2007), while most known plant miRNAs show extensive
complementarity with their targets, directing target mRNA
cleavage (Bartel, 2004; Schwab et al., 2005; Bonnet et al.,
2006).
EXPERIMENTAL PROCEDURES
Constructs and Generation of Point Mutants
The RL-5BoxB, lN-HA-Ago2, and HA-Ago2 constructs were a gener-
ous gift from R. Pillai and W. Filipowicz. pGL3 plasmid expressing FL
was purchased from Promega. Site-directed mutagenesis was per-
formed using the Quickchange XL kit (Stratagene). EMCV-RL-5BoxB
was generated by cloning the 5BoxB sequence in the 30-UTR of
EMCV-RL plasmid (a gift from R. Pillai and W. Filipowicz). Details are
provided in the Supplemental Experimental Procedures.
Cell Culture, Transfections, Luciferase Assays,
and Western Blots
Details are provided in the Supplemental Experimental Procedures.
Immunopurification of lN-HA-Ago2 and lN-HA-Ago2-F2V2
and m7GTP Sepharose Bindings
293T cells (2 3 107) were transfected with 16 mg of appropriate Ago2-
expressing plasmid (lN-HA-Ago2 or lN-HA-Ago2-F2V2). The next
day, the cells from each transfection were split 1:1 (in four 100 mm
dishes) and the cells were harvested 48 hr posttransfection. Immu-
noaffinity purification and elution of proteins was performed as previ-
ously described (Mourelatos et al., 2001). Briefly, the cell pellet was re-
suspended in lysis buffer (20 mM Tris-HCL at pH 7.5, 200 mM NaCl,
2.5 mM MgCl2, and 0.5% Triton X-100 plus protease inhibitors) lysed
by sonication and clarified. The supernatant was used for immunopre-
cipitations with 100 ml of anti-HA agarose resin (16B12 covalently
bound to the agarose matrix, Covance). The resin was then washed
extensively with the same buffer, except that the NaCl concentration
was raised to 500 mM. The final wash was with 20 mM Tris-HCL,1148 Cell 129, 1141–1151, June 15, 2007 ª2007 Elsevier Inc.100 mM NaCl, 2.5 mM MgCl2, and 1 mM DTT. Captured HA-tagged
Ago2 proteins were eluted with 0.1 M glycine at pH 2.5 and neutralized
with 1 M Tris-HCL at pH 8.0 and dialyzed against phosphate-buffered
saline (PBS). Eluates (20 ml) were incubated with 10 ml bed volume of
m7GTP sepharose (GE Healthcare) or with 10 ml bed volume of GTP-
sepharose (Axxora) in 200 ml of binding buffer (20 mM Tris-HCL, 100 mM
NaCl, 2.5 mM MgCl2, 1 mM DTT, and 1 mg/ml heparin) for 1 hr at
4C using constant rotation. The beads were washed four times with
800 ml of 20 mM Tris-HCL, 100 mM NaCl, 2.5 mM MgCl2, and 1 mM
DTT, and the proteins were eluted with NuPAGE sample buffer (Invitro-
gen). As a competitive inhibitor, 75 mM of cap analog (m7GpppG; New
England Biolabs) was added to the binding reaction were indicated;
nonmethylated GpppG (NEB) was also used at 75 mM. Proteins were
analyzed by electrophoresis in 4%–12% NuPAGE (Invitrogen) and
visualized by western blot using the anti-HA monoclonal antibody
16B12 (Covance).
Cellular Fractionation, Polysome Analysis, and Northern Blots
These were performed as previously described (Pillai et al., 2005; Nel-
son et al., 2004), with few modifications. Forty-eight hours posttrans-
fection, cycloheximide (final 100 mg/ml) was added to the cells 5 min
prior to harvest to arrest translation elongation. For each gradient,
the cells from two 100 mm plates were washed with PBS containing
100 mg/ml cycloheximide, trypsinized (again in the presence of
100 mg/ml cycloheximide), combined in one 15 ml Falcon tube, and
washed twice with ice-cold PBS containing 100 mg/ml cycloheximide
and the cell pellet was lysed with 600 ml of lysis buffer (20 mM Tris-
HCL at pH 7.5, 200 mM NaCl, 5 mM MgCl2, 0.5% Triton X-100,
100 mg/ml cycloheximide, 0.1 U/ml Rnasin, complete EDTA-free prote-
ase inhibitors; Roche) on ice by passing the cells four times through
a 25G needle. The lysate was clarified by centrifugation at 14,000 g
for 10 min at 4C. A 50 ml aliquot was removed for total RNA isolation,
and the clarified supernatant was loaded on 10%–50% sucrose gradi-
ents (prepared in a buffer containing 20 mM Tris-HCL at pH 7.5,
200 mM NaCl, and 5 mM MgCl2). All ultracentrifugations were carried
with a SW41 rotor at 4C at 36,000 rpm for 2 hr. Twelve fractions were
collected with a Biocomp collector, and the A254 absorbance was
monitored with a UVM-II monitor (GE healthcare) using a Dataq DI-
158U USB data acquisition interface (Dataq) connected to a PC and
visualized using WinDaq software (Dataq). Total RNA was isolated
from each fraction using Trizol-LS (Invitrogen). The RNA pellet from
each fraction was digested with three units of RQ1 RNase-free DNase
I (Promega) for 15 min at 37C and was then extracted with phenol/
chloroform. The RNA pellet was resuspended in 12 ml of Millipore
H2O, and one-half was used for Northern blots.
To generate riboprobes for hRL and FL, the cDNA inserts from RL-
5BoxB plasmids and pGL3 plasmids were amplified with PCR, using
reverse primers that contained the T7 RNA polymerase promoter
sequence. Primer sequences were the following for hRL: Forward,
hRL-F, 50-ATGGCTTCCAAGGTGTACGACCCCGAG; Reverse, hRL-
T7-R, 50-TAATACGACTCACTATAGGGTTACTGCTCGTTCTTCAGCA
CGCGCTC. Primer sequences were the following for FL: Forward,
FL-F, 50- ATGGAAGACGCCAAAAACATAAAGAAA; Reverse, FL-T7-
R, 50-TAATACGACTCACTATAGGGTTACACGGCGATCTTTCCGCCC
TTCTT. The PCR products were gel purified, and 200 ng of each
was used as template with the Strip-EZ T7 RNA kit (Ambion). In vitro
transcription was performed according to the manufacturer’s instruc-
tions with the following exceptions: 11 ml of [a-32P]UTP at 3000 Ci/
mmol and 2 ml of 67 mM cold UTP was used per reaction. To generate
radiolabeled DNA probe for b-actin, 30 ng of b-actin cDNA (Ambion)
was used in a random priming reaction with 5 ml of [a-32P]dCTP at
3000 Ci/mmol using the Ready-To-Go DNA labeling beads (GE Health-
care). RNA was denatured with glyoxal (Ambion), resolved on 1%
glyoxal-agarose gels, and electroblotted onto Hybond-N+ membranes
(GE Healthcare) using the Transblot SD apparatus (Biorad); electro-
blotting was with 0.53 TBE, at 20 V constant for 1 hr per gel transfer.
Membranes were blocked with Ultrahyb (Ambion) and hybridized
overnight with probes diluted in Ultrahyb at 68C (riboprobes) or at
44C (DNA probes for actin). Membranes were washed twice, 30 min
each with 23 SSC, 0.1% SDS at room temperature and twice, 1 hr
each, with 0.1X SSC, 0.1% SDS at 68C (riboprobes) or at 44C
(DNA probes for actin). Quantitation of signal was performed with stor-
age phospor autoradiography using a Storm 860 (GE Healthcare).
Stripping of the membranes was performed according to Ambion’s
instructions.
Immunoprecipitations and Cleavage Assays
These were performed essentially as described in (Kiriakidou et al.,
2005). For immunoprecipitation of endogenous Ago2 protein, 2 ml of
2A8 ascites was used with 20 ml of protein-G agarose (Invitrogen)
and HeLa cell lysate from one 100 mm dish. For immunoprecipitations
of HA-tagged Ago constructs, lysate from two 100 mm HeLa dishes
transfected with appropriate Ago2-expressing plasmid as described
above was used with 20 ml bed volume of anti-HA (16B12)-conjugated
agarose beads (Covance). Cells were lysed in 20 mM Tris-HCL at pH
7.5, 200 mM NaCl, 2.5 mM MgCl2, 0.5% Triton X-100, and 0.1 U/ml
RNasin, complete EDTA-free protease inhibitors, as described above.
The beads were washed extensively with the same buffer except that
the NaCl concentration was raised to 600 mM. The final washes were
with 20 mM HEPES-KOH at pH 7.5, 100 mM KCl, and 0.5 mM DTT.
Preparation of radiolabeled target complementary to let-7 and cleav-
age assays were performed as previously described (Kiriakidou
et al., 2005). RNA from cleavage assays was resolved using 20%
UREA-PAGE and visualized by autoradiography.
Supplemental Data
Supplemental Data include one figure and Supplemental Experimental
Procedures and can be found with this article online at http://www.cell.
com/cgi/content/full/129/6/1141/DC1/.
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